Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Glaxo moves AZT account to FCB

Published on .

In the wake of the merger creating Glaxo Wellcome, the company moved its Retrovir (also known as AZT) and Mepron HIV/AIDS drug brands to FCB HealthCare, New York and San Francisco, said agency President-CEO John Loden. Harrison, Star, Weiner & Beitler, New York, had handled. FCB HealthCare already had 3TC, another HIV/AIDS drug developed by Glaxo, and the move is considered a consolidation of related drugs.

Copyright September 1995 Crain Communications Inc.

Most Popular
In this article: